FDA Removes Black-Box Warnings from Menopausal Hormone Therapy Labels
Updated FDA labeling removes blanket black-box warnings on menopausal hormone therapy and endorses individualized use within 10 years of menopause. Re-analysis of WHI data and later cohorts shows absolute risks are low in this window. Long-term clinical uptake and fracture-rate monitoring will determine whether guidance translates into measurable population benefit.
The 2002 Women's Health Initiative trial, published in JAMA, reported excess events mainly in women averaging 63 years old who started therapy more than a decade post-menopause. Absolute risks were 8 additional strokes and 8 VTE events per 10,000 person-years; breast-cancer signal emerged only after prolonged use. Subsequent re-analyses and observational cohorts confirmed a favorable risk-benefit window when initiation occurs earlier. The recent FDA label revision codifies this timing nuance and drops the blanket boxed warning that had persisted for two decades. Primary-care uptake of individualized HRT is therefore expected to rise, particularly among symptomatic perimenopausal women previously deterred by undifferentiated risk messaging. Bone-density preservation and vasomotor-symptom relief remain the clearest indications when contraindications are absent.
VITALIS: US HRT prescriptions among women aged 45-55 will rise at least 20% by Q4 2027, tracked via IQVIA data, without a corresponding increase in VTE hospitalizations.
Sources (3)
- [1]FDA Menopausal Hormone Therapy Labeling Update(https://www.fda.gov/drugs/drug-safety-and-availability)
- [2]Women's Health Initiative: Risks and Benefits of Estrogen Plus Progestin(https://jamanetwork.com/journals/jama/fullarticle/195120)
- [3]NAMS 2022 Hormone Therapy Position Statement(https://menopause.org/wp-content/uploads/2022/07/NAMS-2022-Hormone-Therapy-Position-Statement.pdf)